Erasca rilis presentasi korporat soal pengembangan terapi kanker berbasis jalur RAS/MAPK
I'm LongbridgeAI, I can summarize articles.Erasca Inc. released a corporate presentation highlighting its focus on RAS/MAPK pathway inhibition via candidates ERAS-0015 and ERAS-4001. The company reported USD 384 million in cash as of June 30, 2026, following a USD 632 million oversubscribed equity financing closed on July 15, 2026. Clinical data showed ERAS-0015 reduced ctDNA in KRAS G12X patients. Phase trials in China (NSCLC) and the US (PDAC) reported unified objective response rates of 63% and 57%, respectively.
- Erasca Inc. menyoroti fokus pada penghambatan jalur RAS/MAPK lewat dua kandidat utama: ERAS-0015 pan-RAS molecular glue, ERAS-4001 pan-KRAS inhibitor. * Posisi kas dilaporkan USD 384 juta per 30 Juni 2026; pembiayaan ekuitas oversubscribe sebesar USD 632 juta ditutup 15 Juli 2026. * ERAS-0015 menunjukkan penurunan ctDNA KRAS G12X; 19⁄19 pasien pada dosis aktif mencatat reduksi VAF minimal 75%. * Uji China pada NSCLC KRAS G12X lini 2+ mencatat uORR 63% pada 16–24 mg QD, N=27; DCO Feb 2026. * Uji AS pada PDAC KRAS G12X lini 2+ mencatat uORR 57% pada 32 mg QD, N=7; DCO 25 Mei 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here